IONS
Ionis Pharmaceuticals, Inc.$54.59-0.34 (-0.63%)Prev Close$54.93·MCap$9.63B·P/E—·Vol1.65M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
114
$189.01M
◆
Net Activity
Net Seller
$189.01M
●
Active Insiders
19
last 12 mo
Over the past 12 months, insider activity at Ionis Pharmaceuticals, Inc. (IONS) has been exclusively selling, with 0 insider purchases totaling $0.00 and 114 insider sales totaling $189.01M. The most recent insider transaction was by Diaz Allene M. (director), who sold $863.6K worth of shares on Jul 9, 2026. Ionis Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $9.63B.
IONS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Diaz Allene M. | director | Sell | 10,111 | $85.42 | $863.6K | 3,811-73% |
| Jul 9, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 20,536 | $84.95 | $1.74M | 75,018 |
| Jul 9, 2026 | Kordasiewicz Holly B. | officer: EVP, Chief Development Officer | Sell | 362 | $84.30 | $30.5K | 22,096 |
| Jul 6, 2026 | KLEIN JOSEPH III | director | Sell | 11,518 | $79.04 | $910.4K | 22,433-34% |
| Jun 30, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 26,000 | $81.05 | $2.11M | 77,114-25% |
| Jun 30, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,635 | $80.16 | $451.7K | 4,669-55% |
| Jun 30, 2026 | O'NEIL PATRICK R. | officer: EVP CLO & General Counsel | Sell | 3,069 | $80.00 | $245.5K | 61,470 |
| Jun 26, 2026 | Swayze Eric | officer: EVP Research | Sell | 10,602 | $79.18 | $839.5K | 21,759-33% |
| Jun 26, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 85,637 | $79.70 | $6.83M | 245,571-26% |
| Jun 16, 2026 | Kordasiewicz Holly B. | officer: EVP, Chief Development Officer | Sell | 60,846 | $73.41 | $4.47M | 42,300-59% |
| Jun 16, 2026 | BERTHELSEN SPENCER R | director | Sell | 8,000 | $73.49 | $587.9K | 156,013 |
| Jun 3, 2026 | BERTHELSEN SPENCER R | director | Sell | 8,000 | $75.67 | $605.4K | 156,013 |
| May 15, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 4,536 | $78.49 | $356.0K | 242,662 |
| May 6, 2026 | LOSCALZO JOSEPH | director | Sell | 77,289 | $75.06 | $5.80M | 54,111-59% |
| May 5, 2026 | KLEIN JOSEPH III | director | Sell | 10,111 | $73.51 | $743.2K | 12,445-45% |
| Apr 30, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 1,626 | $71.79 | $116.7K | 44,909 |
| Apr 17, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $76.27 | $381.4K | 51,878 |
| Apr 17, 2026 | Jenne Kyle | officer: EVP, Chf GL Pdt Str Ofcr | Sell | 4,902 | $75.17 | $368.5K | 23,713 |
| Apr 17, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,619 | $74.56 | $419.0K | 46,535 |
| Apr 17, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 973 | $75.04 | $73.0K | 67,500 |
| Apr 2, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 6,193 | $74.05 | $458.6K | 16,348-27% |
| Apr 2, 2026 | KLEIN JOSEPH III | director | Sell | 22,321 | $75.55 | $1.69M | 13,230-63% |
| Mar 23, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 5,812 | $70.97 | $412.5K | 63,890 |
| Mar 18, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 225,220 | $72.43 | $16.31M | 102,272-69% |
| Mar 5, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 6,421 | $79.73 | $511.9K | 41,317 |
| Mar 5, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 85,089 | $79.23 | $6.74M | 94,043-48% |
| Mar 5, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 20,106 | $79.40 | $1.60M | 28,326-42% |
| Mar 5, 2026 | Diaz Allene M. | director | Sell | 54,878 | $79.35 | $4.35M | 19,424-74% |
| Mar 5, 2026 | KLEIN JOSEPH III | director | Sell | 21,332 | $79.51 | $1.70M | 18,820-53% |
| Mar 5, 2026 | LOSCALZO JOSEPH | director | Sell | 1,032 | $80.26 | $82.8K | 36,330 |
| Feb 13, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $82.72 | $413.6K | 56,344 |
| Feb 13, 2026 | Swayze Eric | officer: EVP Research | Sell | 31,284 | $81.76 | $2.56M | 38,312-45% |
| Feb 11, 2026 | PARSHALL B LYNNE | Director | Sell | 5,000 | $82.72 | $413.6K | 0 |
| Feb 10, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 254,497 |
| Feb 6, 2026 | Monia Brett P | Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 0 |
| Feb 4, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 36,463 | $82.79 | $3.02M | 80,293-31% |
| Feb 2, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 45,413 |
| Feb 2, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 90,974 | $82.93 | $7.54M | 100,293-48% |
| Feb 2, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 66,247 |
| Feb 2, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 132,881 |
| Feb 2, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 283,927 |
| Feb 2, 2026 | O'NEIL PATRICK R. | officer: EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516.2K | 71,983 |
| Feb 2, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 6,179 | $83.45 | $515.6K | 69,702 |
| Feb 2, 2026 | Swayze Eric | officer: EVP Research | Sell | 6,179 | $82.93 | $512.4K | 47,747 |
| Jan 29, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 0 |
| Jan 29, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | Sell | 5,885 | $82.95 | $488.1K | 0 |
| Jan 29, 2026 | Birchler Brian | EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 0 |
| Jan 29, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 0 |
| Jan 29, 2026 | Monia Brett P | Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 0 |
| Jan 29, 2026 | O'NEIL PATRICK R. | EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516.2K | 0 |
Showing 1–50 of 121
1 / 3
IONS Insider Buying Activity
The following table shows recent insider purchases of Ionis Pharmaceuticals, Inc. (IONS) stock reported via SEC Form 4 filings.
No insider buying activity found for IONS in the last 12 months.
IONS Insider Selling Activity
The following table shows recent insider sales of Ionis Pharmaceuticals, Inc. (IONS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Diaz Allene M. | director | Sell | 10,111 | $85.42 | $863.6K | 3,811-73% |
| Jul 9, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 20,536 | $84.95 | $1.74M | 75,018 |
| Jul 9, 2026 | Kordasiewicz Holly B. | officer: EVP, Chief Development Officer | Sell | 362 | $84.30 | $30.5K | 22,096 |
| Jul 6, 2026 | KLEIN JOSEPH III | director | Sell | 11,518 | $79.04 | $910.4K | 22,433-34% |
| Jun 30, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 26,000 | $81.05 | $2.11M | 77,114-25% |
| Jun 30, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,635 | $80.16 | $451.7K | 4,669-55% |
| Jun 30, 2026 | O'NEIL PATRICK R. | officer: EVP CLO & General Counsel | Sell | 3,069 | $80.00 | $245.5K | 61,470 |
| Jun 26, 2026 | Swayze Eric | officer: EVP Research | Sell | 10,602 | $79.18 | $839.5K | 21,759-33% |
| Jun 26, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 85,637 | $79.70 | $6.83M | 245,571-26% |
| Jun 16, 2026 | Kordasiewicz Holly B. | officer: EVP, Chief Development Officer | Sell | 60,846 | $73.41 | $4.47M | 42,300-59% |
| Jun 16, 2026 | BERTHELSEN SPENCER R | director | Sell | 8,000 | $73.49 | $587.9K | 156,013 |
| Jun 3, 2026 | BERTHELSEN SPENCER R | director | Sell | 8,000 | $75.67 | $605.4K | 156,013 |
| May 15, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 4,536 | $78.49 | $356.0K | 242,662 |
| May 6, 2026 | LOSCALZO JOSEPH | director | Sell | 77,289 | $75.06 | $5.80M | 54,111-59% |
| May 5, 2026 | KLEIN JOSEPH III | director | Sell | 10,111 | $73.51 | $743.2K | 12,445-45% |
| Apr 30, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 1,626 | $71.79 | $116.7K | 44,909 |
| Apr 17, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $76.27 | $381.4K | 51,878 |
| Apr 17, 2026 | Jenne Kyle | officer: EVP, Chf GL Pdt Str Ofcr | Sell | 4,902 | $75.17 | $368.5K | 23,713 |
| Apr 17, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,619 | $74.56 | $419.0K | 46,535 |
| Apr 17, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 973 | $75.04 | $73.0K | 67,500 |
| Apr 2, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 6,193 | $74.05 | $458.6K | 16,348-27% |
| Apr 2, 2026 | KLEIN JOSEPH III | director | Sell | 22,321 | $75.55 | $1.69M | 13,230-63% |
| Mar 23, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 5,812 | $70.97 | $412.5K | 63,890 |
| Mar 18, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 225,220 | $72.43 | $16.31M | 102,272-69% |
| Mar 5, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 6,421 | $79.73 | $511.9K | 41,317 |
| Mar 5, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 85,089 | $79.23 | $6.74M | 94,043-48% |
| Mar 5, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 20,106 | $79.40 | $1.60M | 28,326-42% |
| Mar 5, 2026 | Diaz Allene M. | director | Sell | 54,878 | $79.35 | $4.35M | 19,424-74% |
| Mar 5, 2026 | KLEIN JOSEPH III | director | Sell | 21,332 | $79.51 | $1.70M | 18,820-53% |
| Mar 5, 2026 | LOSCALZO JOSEPH | director | Sell | 1,032 | $80.26 | $82.8K | 36,330 |
| Feb 13, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $82.72 | $413.6K | 56,344 |
| Feb 13, 2026 | Swayze Eric | officer: EVP Research | Sell | 31,284 | $81.76 | $2.56M | 38,312-45% |
| Feb 11, 2026 | PARSHALL B LYNNE | Director | Sell | 5,000 | $82.72 | $413.6K | 0 |
| Feb 10, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 254,497 |
| Feb 6, 2026 | Monia Brett P | Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 0 |
| Feb 4, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 36,463 | $82.79 | $3.02M | 80,293-31% |
| Feb 2, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 45,413 |
| Feb 2, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 90,974 | $82.93 | $7.54M | 100,293-48% |
| Feb 2, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 66,247 |
| Feb 2, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 132,881 |
| Feb 2, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 283,927 |
| Feb 2, 2026 | O'NEIL PATRICK R. | officer: EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516.2K | 71,983 |
| Feb 2, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 6,179 | $83.45 | $515.6K | 69,702 |
| Feb 2, 2026 | Swayze Eric | officer: EVP Research | Sell | 6,179 | $82.93 | $512.4K | 47,747 |
| Jan 29, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 0 |
| Jan 29, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | Sell | 5,885 | $82.95 | $488.1K | 0 |
| Jan 29, 2026 | Birchler Brian | EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 0 |
| Jan 29, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 0 |
| Jan 29, 2026 | Monia Brett P | Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 0 |
| Jan 29, 2026 | O'NEIL PATRICK R. | EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516.2K | 0 |
IONS Insiders
Similar Stocks to IONS
VRTX
Vertex Pharmaceuticals Incorporated
$477.45+0.18%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$661.90+0.88%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$279.67-0.60%
$43.19B
RVMD
Revolution Medicines, Inc.
$184.79-0.09%
$40.34B
MRNA
Moderna, Inc.
$67.55+0.16%
$27.09B
INSM
Insmed Incorporated
$109.58-0.48%
$25.06B
INCY
Incyte Corporation
$114.75-0.11%
$23.32B
UTHR
United Therapeutics Corporation
$530.82+0.79%
$23.22B